Pluri Inc. (NASDAQ: PLUR) announced that its subsidiary Cellav Health and Aesthetics Ltd. has completed U.S. cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, enabling commercial launch in the United States.

The products are now listed under the U.S. cosmetic framework and FDA regulation. Cellav is conducting discussions with U.S. distributors, clinic networks and strategic partners across the United States, United Kingdom and additional international markets.

Regenativo+ is a plant-derived treatment, while Placento+ is a placenta-derived formulation. Both products are supplied in Cellav's DUO format consisting of a lyophilized powder vial paired with a booster vial, designed for topical professional use following aesthetic procedures.

Clinical studies of Cellav's ingredients showed statistically significant improvements in skin distensibility, elasticity, firmness and skin-fatigue index using plant-based extracellular vesicles ingredients. A separate study using placenta-based secretome and exosomes demonstrated significant improvements in vascular tone and brown discoloration, with additional improvements in pigmented spots observed in subjects with higher baseline values.

"Our first U.S. commercial launch through Cellav opens access to one of the fastest-growing and highest-margin segments in consumer health," said Yaky Yanay, President and Chief Executive Officer of Pluri.

Katty Dowery, Chief Executive Officer of Cellav, stated that the milestone "represents the transition of Cellav from product development to commercialization."

Pluri operates in regenerative medicine, longevity, foodtech and agtech fields using its 3D cell expansion technology platform. The company also offers Contract Development and Manufacturing Organization services.